HealthEquity vs Protagonist Therapeutics

HealthEquity (HQY), health care, and Protagonist Therapeutics (PTGX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

HealthEquity is worth $8.4B on the stock market and Protagonist Therapeutics $8.1B: HealthEquity is valued at 4% more. HealthEquity trades at 36.8 times earnings and Protagonist Therapeutics at 26.4; operating margins in their latest fiscal years were 24.6% and -344%. Over the past year HealthEquity's share price has moved +1.79% and Protagonist Therapeutics's +47.9%.

Key facts

HealthEquity market value
$8.4B
Protagonist Therapeutics market value
$8.1B
HealthEquity P/E
36.8
Protagonist Therapeutics P/E
26.4
HealthEquity revenue
$1.3BFY to 2026-01-31
Protagonist Therapeutics revenue
$46MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

HealthEquity vs Protagonist Therapeutics: every measure side by side
Measure HealthEquity Protagonist Therapeutics
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2026-01-312025-12-31
Size
Market cap$8.4Bhigher$8.1Blower
Revenue$1.3Bhigher$46Mlower
Earnings$215.2Mhigher-$130.1Mlower
Employees2,814higher149lower
Total assets$3.4Bhigher$668.2Mlower
Valuation
P/E36.8higher26.4lower
P/S6.4lower177higher
P/B4.2lower7.5higher
Dividend yield0.00%0.00%
Profitability
Operating margin24.6%higher-344%lower
Balance sheet
Net assets$2.1Bhigher$614.7Mlower
Total liabilities$1.3Bhigher$53.5Mlower
Total debt$957.4M—
Cash on hand$318.9Mhigher$128.4Mlower
Price change
Today-2.62%lower-0.13%higher
1 year+1.79%lower+47.9%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

HealthEquity only (1)

Protagonist Therapeutics only (3)

Percentages are each holding's share of that investor's reported portfolio. Who owns HQY · Who owns PTGX

Further comparisons

Learn

Questions and answers

Which is bigger, HealthEquity or Protagonist Therapeutics?

By market value, HealthEquity is the larger: $8.4B against $8.1B for Protagonist Therapeutics. By revenue in its latest fiscal year, HealthEquity is the larger: $1.3B against $46M for Protagonist Therapeutics.

Which has the higher P/E ratio?

HealthEquity: 36.8, against 26.4 for Protagonist Therapeutics. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

HealthEquity: 24.6%, against -344% for Protagonist Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both HealthEquity and Protagonist Therapeutics?

None of the tracked superinvestors holds both in their latest 13F filing. 1 holds HealthEquity and 3 hold Protagonist Therapeutics.

Cite this page

Funkfolio, “HealthEquity vs Protagonist Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/hqy-vs-ptgx

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.